An adapted passive model of anti-MPO dependent crescentic glomerulonephritis reveals matrix dysregulation and is amenable to modulation by CXCR4 inhibition.


Journal

Matrix biology : journal of the International Society for Matrix Biology
ISSN: 1569-1802
Titre abrégé: Matrix Biol
Pays: Netherlands
ID NLM: 9432592

Informations de publication

Date de publication:
02 2022
Historique:
received: 31 08 2021
revised: 18 12 2021
accepted: 05 01 2022
pubmed: 16 1 2022
medline: 25 3 2022
entrez: 15 1 2022
Statut: ppublish

Résumé

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are severe inflammatory disorders that often involve focal necrotizing glomerulonephritis (FNGN) and consequent glomerular scarring, interstitial fibrosis, and chronic kidney disease. Robust murine models of scarring in FNGN that may help to further our understanding of deleterious processes are still lacking. Here, we present a murine model of severe FNGN based on combined administration of antibodies against the glomerular basement membrane (GBM) and myeloperoxidase (MPO), and bacterial lipopolysaccharides (LPS), that recapitulates acute injury and was adapted to investigate subsequent glomerular and interstitial scarring. Hematuria without involvement of other organs occurs consistently and rapidly, glomerular necrosis and crescent formation are evident at 12 days, and consequent glomerular and interstitial scarring at 29 days after initial treatment. Using mass-spectrometric proteome analysis, we provide a detailed overview of matrisomal and cellular changes in our model. We observed increased expression of the matrisome including collagens, fibronectin, tenascin-C, in accordance with human AAV as deduced from analysis of gene expression microarrays and tissue staining. Moreover, we observed tissue infiltration by neutrophils, macrophages, T cells and myofibroblasts upon injury. Experimental inhibition of CXCR4 using AMD3100 led to a sustained histological presence of fibrin extravasate, reduced chemokine expression and leukocyte activation, but did not markedly affect ECM composition. Altogether, we demonstrate an adapted FNGN model that enables the study of matrisomal changes both in disease and upon intervention, as exemplified via CXCR4 inhibition.

Identifiants

pubmed: 35032611
pii: S0945-053X(22)00001-4
doi: 10.1016/j.matbio.2022.01.001
pii:
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0
CXCR4 protein, human 0
Receptors, CXCR4 0
Peroxidase EC 1.11.1.7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-33

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interests The authors declare no competing financial interests.

Auteurs

Chérine Abou Fayçal (CA)

INSERM U1109, The Tumor Microenvironment Laboratory, Strasbourg, France; Université Strasbourg, Hopital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; These authors (CAF and AO) contributed equally to this work.

Andre Oszwald (A)

Department of Pathology, Medical University of Vienna, Vienna, Austria; These authors (CAF and AO) contributed equally to this work.

Tobias Feilen (T)

Institute of Surgical Pathology, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Schänzlestraße 1, 79104 Freiburg, Germany.

Miguel Cosenza-Contreras (M)

Institute of Surgical Pathology, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Schänzlestraße 1, 79104 Freiburg, Germany.

Oliver Schilling (O)

Institute of Surgical Pathology, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK) and Cancer Research Center (DKFZ), Hugstetter Straße 55, 79106 Freiburg, Germany.

Thomas Loustau (T)

INSERM U1109, The Tumor Microenvironment Laboratory, Strasbourg, France; Université Strasbourg, Hopital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.

Fanny Steinbach (F)

INSERM U1109, The Tumor Microenvironment Laboratory, Strasbourg, France; Université Strasbourg, Hopital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.

Helga Schachner (H)

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Brigitte Langer (B)

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Peter Heeringa (P)

Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Andrew J Rees (AJ)

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Gertraud Orend (G)

INSERM U1109, The Tumor Microenvironment Laboratory, Strasbourg, France; Université Strasbourg, Hopital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France. Electronic address: gertraud.orend@inserm.fr.

Renate Kain (R)

Department of Pathology, Medical University of Vienna, Vienna, Austria. Electronic address: renate.kain@meduniwein.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH